SGN-B6AA Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor:

Seagen, a wholly owned subsidiary of Pfizer

Code:

NCT04389632

Conditions

Carcinoma, Non-Small Cell Lung

Squamous Cell Carcinoma of Head and Neck

HER2 Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Esophageal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

sigvotatug vedotin

pembrolizumab

cisplatin

carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-23. This information was provided to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer on 2026-07-06.